- Home
- BEN vs NBIX Comparison
BEN vs NBIX Comparison
Compare BEN & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEN
- NBIX
- Stock Information
- Founded
- BEN 1947
- NBIX 1992
- Country
- BEN United States
- NBIX United States
- Employees
- BEN N/A
- NBIX N/A
- Industry
- BEN Investment Managers
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BEN Finance
- NBIX Health Care
- Exchange
- BEN Nasdaq
- NBIX Nasdaq
- Market Cap
- BEN 10.7B
- NBIX 11.8B
- IPO Year
- BEN N/A
- NBIX 1996
- Fundamental
- Price
- BEN $21.97
- NBIX $125.65
- Analyst Decision
- BEN Sell
- NBIX Buy
- Analyst Count
- BEN 13
- NBIX 24
- Target Price
- BEN $21.87
- NBIX $163.91
- AVG Volume (30 Days)
- BEN 4.3M
- NBIX 1.1M
- Earning Date
- BEN 11-04-2024
- NBIX 10-30-2024
- Dividend Yield
- BEN 5.65%
- NBIX N/A
- EPS Growth
- BEN N/A
- NBIX 97.40
- EPS
- BEN 0.85
- NBIX 3.73
- Revenue
- BEN $8,478,000,000.00
- NBIX $2,242,800,000.00
- Revenue This Year
- BEN N/A
- NBIX $26.97
- Revenue Next Year
- BEN $3.66
- NBIX $16.69
- P/E Ratio
- BEN $25.89
- NBIX $33.47
- Revenue Growth
- BEN 8.01
- NBIX 25.72
- 52 Week Low
- BEN $18.95
- NBIX $110.52
- 52 Week High
- BEN $30.32
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- BEN 63.09
- NBIX 58.45
- Support Level
- BEN $21.40
- NBIX $115.27
- Resistance Level
- BEN $21.93
- NBIX $129.67
- Average True Range (ATR)
- BEN 0.46
- NBIX 3.37
- MACD
- BEN 0.04
- NBIX 0.10
- Stochastic Oscillator
- BEN 97.44
- NBIX 72.08
About BEN Franklin Resources Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2024, Franklin had $1.681 trillion in managed assets, composed primarily of equity (36%), fixed-income (34%), multi-asset/balanced (10%) funds, alternatives (15%) and money market funds (5%). Distribution tends to be weighted equally between retail investors (52% of AUM) and institutional accounts (46%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the US-based asset managers we cover, with 30% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.